Skip to content

Clinical Study of Absorbable Sutures

Post Market Clinical Follow Up Study of Absorbable Sutures

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039498
Enrollment
300
Registered
2022-01-17
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Absorbable Surgical sutures: Absorbable sutures should be selected and implanted depending on the patient�s condition, surgical experience, surgical technique and wound size. Pec

Sponsors

Futura Surgicare Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Informed consent from the subject Subjects using the absorbable sutures for general surgery, soft tissue approximation and ligation. Adult patient who are � 18 age.

Exclusion criteria

Exclusion criteria: Subjects without informed consent from the subject. Subject in which extended approximation of tissues under stress is required. Subject who are sensitive or allergic to the raw materials of the sutures.

Design outcomes

Primary

MeasureTime frame
The primary objective of this post market clinical study is to assess the clinical performance, safety and acceptability of the Absorbable Surgical Suture. Endpoints - Quantitative determination of soft tissue approximation/ligation and wound closure action by using the Absorbable surgical suture - Occurrence of wound reopening - Occurrence of wound re-rupturing after hand surgery - Any signs of superficial infection after surgery ââ?¬â?? Redness, Pus, Swelling - Ease of use using Likertââ?¬â?¢s scale (1-5) Timepoint: 6 to 12 months

Secondary

MeasureTime frame
The Secondary Objective is to determine any undesirable events under normal condition of use and identify the presence of any new emergent risks, known and unknown residual risk. The study will focus on identifying possible systematic misuse or off-label use of the device.Timepoint: 6 to 12 months

Countries

India

Contacts

Public ContactDr Murali Mohan S

Sagar Hospitals

drmurali78@gmail.com9483861505

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026